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Role of IFNα in the pathogenesis of systemic lupus 
erythematosus
Systemic lupus erythematosus (SLE) is an autoimmune 
disease characterized by multiple immune system abnor-
malities, including production of autoantibodies that can 
lead to inﬂ  ammation and tissue damage [1]. SLE symp-
toms can range from a mild rash to life-threatening 
nephritis and central nervous system disease. Th  ese 
disease manifestations cause a signiﬁ   cant burden of 
illness and can cause reduced physical function, loss of 
employment, lower health-related quality of life, and a 
lifespan shortened by about 10 years [2]. Increased 
hospitalizations and side eﬀ  ects of medications including 
chronic corticosteroid and other immunosuppressive 
treatments add to the disease burden in SLE [2]. No new 
treatment for SLE has been approved by the US Food and 
Drug Administration in about 50 years since hydroxy-
chloroquine was approved for use in discoid lupus and 
SLE; otherwise, the existing standard of care for SLE 
consists of oﬀ  -label medications.
Th   e disease pathogenesis of SLE includes activation of 
innate immunity, with increased production of type I 
interferons, including IFNα, and increased plasmacytoid 
and myeloid dendritic cells in involved tissue [3-8]. 
Speciﬁ  c immunity, including both humoral and cellular 
immune systems, is activated. Autoantibodies are univer-
sally present and may precede development of clinically 
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© 2010 BioMed Central Ltdapparent disease [9]. SLE-associated autoantibodies 
include anti-dsDNA, anti-nucleosomes, anti-RNP (ribo-
nucleo  protein complex), and anti-Sm antibodies. Immune 
complexes containing anti-dsDNA or anti-RNP anti-
bodies can activate type I interferon production [3,4]. 
After internalization through Fc receptors, autoantibody-
containing immune complexes bind endosomal Toll-like 
receptors 7 and 9, and stimulate production of type I 
interferon. Type I interferon stimulates myeloid dendritic 
cell maturation, which promotes loss of tolerance and 
generation of autoreactive T cells and B cells, auto-
antibody production, immune complex formation and 
further production of type I interferon, creating a self-
perpetuating cycle of autoimmunity [5,10,11].
Type I interferons include 14 IFNα family members, 
IFNβ, IFNτ, IFNκ and IFNω [12]. Th  is cytokine family 
regulates immune functions of cellular components of 
both innate and adaptive immune systems, including 
dendritic cells, T cells, B cells, and natural killer cells. For 
example, type I interferons promote dendritic cell matura-
tion, memory CD8+ T-cell proliferation, natural killer-cell 
activation, and B-cell diﬀ  erentiation [5,13]. Type I inter-
ferons also enhance the expression of immuno logically 
important molecules such as MHC class I, CD38, inter-
leukins such as BLyS, IL-6, IL-10 and IL-15, and multiple 
chemokines [14-17].
Emerging data indicate a role for type I interferons in 
disease pathogenesis in SLE. Genetic polymorphisms 
associated with type I interferon pathways are associated 
with susceptibility to SLE [18,19]. Treatment with IFNα 
has been associated with the development of autoanti-
bodies and new or worsening clinical features of the SLE 
[20,21]. Higher IFNα levels and type I interferon activity 
are associated with greater disease activity in SLE [3,7]. 
Patients with high anti-dsDNA antibody titers, lupus 
nephritis, and progressive skin rashes have high serum 
levels of IFNα [3]. In addition, patients with acute skin 
involvement tend to have elevated IFNα in blood and 
skin [7].
Th   ese clinical observations in humans are supported by 
data that show a key role for type I interferon in animal 
models of SLE. IFNα can induce glomerulonephritis in 
normal mice and accelerates the onset of the spontaneous 
autoimmune disease of NZB/W mice [22]. Autoimmune-
predisposed mice deﬁ  cient in the IFNα/β receptor exhibit 
signiﬁ   cantly reduced anti-erythrocyte autoantibodies, 
hemolytic anemia, anti-DNA autoantibodies, kidney 
disease, and mortality [23]. Furthermore, IFNα kinoid 
vaccine has been shown to induce neutralizing antibodies 
to prevent clinical manifestations in a lupus ﬂ  are murine 
model [24].
Together, these human and animal data support the 
hypothesis that inhibiting type I interferon may reduce 
disease activity in SLE.
Increased expression of the type I interferon 
signature in the blood and involved tissues of SLE 
patients
Molecular signatures or mRNA expression patterns in 
the periphery and disease tissues have been used to 
identify novel therapeutic targets and to predict patients 
that might respond favorably to therapeutic interventions 
[25-28]. One distinct observation in SLE is the robust and 
prevalent overexpression of type I interferon-inducible 
mRNAs (type I interferon signature) in the blood and 
involved tissues of patients. Increased expression of 
mRNAs induced by type I interferon is prominent in 
peripheral blood mononuclear cells and in whole blood 
(WB) in approximately 60% of SLE patients, and is asso-
ciated with greater disease activity [29-34]. Type I inter-
feron is the most activated signaling pathway and type I 
interferon-inducible mRNAs are the most overexpressed 
mRNAs in WB of patients with SLE [35]. Skin biopsies 
from a subset of patients with SLE also show increased 
expression of a type I interferon signature [36-38]. 
Expression of type I interferon-inducible IP-10/CXCL10 
mRNAs is increased in SLE patients with active central 
nervous system symptoms [39]. Selected type I 
interferon-inducible mRNAs (IFI44, IFI27, and IFI44L) 
and type I interferon-inducible proteins (IFI27, STAT1) 
are overexpressed in the synovium of SLE patients with 
arthritis [40].
Detection of type I interferon proteins by ELISA has 
yielded positive results in only a small population of SLE 
patients [41], whereas detection of overexpression of the 
type I interferon signature is positive in about 60% of 
patients overall. Th  is discrepancy suggests the type I 
interferon signature is the more sensitive measurement 
to detect increased type I interferon activity in SLE. Th  e 
type I interferon-signature thus provides a potential 
pharma  co  dynamic (PD) marker to evaluate inhibition of 
the molecular target and to help guide dose selection for 
anti-type I interferon therapies in SLE.
Increased expression of the type I interferon 
signature in other rheumatic diseases
In addition to SLE, overexpression of the type I interferon 
signature has been reported in the peripheral blood of 
patients with a variety of inﬂ  ammatory and autoimmune 
diseases that include dermatomyositis, polymyositis, 
multiple sclerosis, rheumatoid arthritis, scleroderma and 
Sjögren’s syndrome [42-46]. Th  e presence of increased 
numbers of plasmacytoid dendritic cells and over-
expression of type I interferon-inducible mRNAs and/or 
proteins has also been reported at the disease tissues in 
some of the diseases [47,48].
Figure 1 shows a heatmap of the relative expression of 807 
type  I interferon-inducible mRNAs (identiﬁ  ed by ex vivo 
stimulation of healthy donor WB with type I interferon 
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22 dermatomyositis patients, 20 polymyo  sitis patients, 
and 66 rheumatoid arthritis subjects compared with 24 
normal healthy control individuals. For each autoimmune 
disease (blocks of columns), the subjects (individual 
columns) are sorted, from left to right, from those 
showing the greatest overexpression of the 807 type I 
interferon-inducible mRNAs (deﬁ  ned as the median fold 
change for each of the 807 mRNAs versus healthy 
controls; rows) to those with the least expression. When 
compared with the 24 normal healthy control individuals, 
a subpopulation of patients within each of these auto-
immune diseases demonstrated overexpression of the 
type I interferon signature in WB.
Th  e evidence that the type I interferon signature is 
highly overexpressed in peripheral blood and tissue in 
multiple autoimmune diseases raises an important 
question as to whether type I interferon is involved in the 
pathogenesis of these diseases, and whether the 
activation of this signaling pathway is shared among the 
diseases. One key issue that needs to be addressed is 
whether activation of the type I interferon signaling 
pathway is concordant in WB and disease tissues of 
patients with these autoimmune diseases. Further  more, it 
remains to be seen whether targeting type I interferon 
could beneﬁ   t a subgroup of patients with distinct 
rheumatic diseases where the diﬀ  erent  disease 
pathogenesis and manifestations are diﬀ  erent.
Development of the type I interferon signature as a 
pharmacodynamic marker for sifalimumab
Sifalimumab is a fully human IgG1κ monoclonal antibody 
that was generated by Medarex in mice transgenic for 
human immunoglobulin genes. Th  e type I interferon 
signature was chosen as a potential PD marker to test 
whether sifalimumab inhibited its intended target, IFNα, 
in early clinical trials in SLE. Th  is choice was made 
because increased expression of type I interferon-
inducible mRNAs is a direct molecular consequence of 
increased expression of IFNα proteins, and because type 
I interferon-induced mRNAs are easy to measure by 
either RT-PCR or microarray-based technologies and 
demonstrate concordant overexpression in blood and 
involved tissue in SLE [38].
A three-tiered approach was taken to develop a panel 
of type I interferon-inducible mRNAs as potential PD 
markers for sifalimumab in SLE. First, the prevalence and 
magnitude of the overexpression of type I interferon 
mRNAs was determined in WB of SLE patients. WB 
samples from healthy donors were stimulated ex vivo 
with each of 10 IFNα subtypes or IFNβ, and then mRNAs 
(n = 807) were identiﬁ  ed that were uniformly upregulated.
Secondly, mRNA expression was measured in the WB 
from 41 SLE patients and compared with mRNA 
expression in the WB of 24 normal healthy controls, 
using signiﬁ  cance analysis of microarrays and the false 
discovery rate. Overall, 110 of the overexpressed mRNAs 
in the WB of these SLE patients were type I interferon-
inducible, with type I interferon-inducible mRNAs among 
the most overexpressed mRNAs in the WB of SLE 
patients. Th   e type I interferon signaling pathway was the 
most activated pathway in WB of these SLE patients. 
Th   ese results were conﬁ  rmed in an independent set of 56 
SLE WB samples.
Finally, mRNAs were identiﬁ  ed whose expression was 
both stimulated when healthy donor peripheral blood 
mononuclear cells were exposed ex vivo to SLE patient 
sera and inhibited by sifalimumab in a dose-dependent 
manner in the same culture system. Overall, 77 type I 
interferon-inducible mRNAs were identiﬁ   ed as over-
expressed in each of the three diﬀ  erent experiments. A 
subset of 21 of these 77 mRNAs was selected to be used 
as candidate PD biomarkers for sifalimumab in SLE, 
based on the magnitude and prevalence of overexpression 
in SLE [35]. In the end, this three-tiered approach yielded 
a small, robust panel of type I interferon-inducible 
mRNAs that could be used in a high-throughput PD 
biomarker assay to evaluate target inhibition by sifalimu-
mab in SLE trials.
Th  e 21-mRNA panel demonstrated many desirable 
characteristics for a PD biomarker. Overexpression of the 
mRNAs within this panel provides a sensitive and speciﬁ  c 
Figure 1. Relative expression of type I interferon-inducible 
mRNAs in the whole blood of rheumatic disease patients. 
Representative heatmap visualizing the relative expression of 807 
type I interferon-inducible mRNAs in whole blood from 106 systemic 
lupus erythematosus (SLE) subjects (red), 20 polymyositis (PM) 
subjects (green), 22 dermatomyositis (DM) subjects (blue), and 66 
rheumatoid arthritis (RA) subjects (pink) compared with whole blood 
from 24 healthy subjects (black). Fold change values are graphed for 
each subject and are grouped by disease.
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WB of SLE patients [35,38]. Elevated expression versus 
normal expression of this mRNA panel was a consistent 
characteristic of an individual SLE patient, in the absence 
of therapeutic intervention with sifalimumab [29-35], 
which allows normalization of expression of this PD 
biomarker to be interpreted as treatment eﬀ  ect. Expres-
sion of the mRNAs within this panel can be measured 
quantitatively by multiple assays [35], allowing ﬂ  exibility 
of the approach during clinical testing.
Th   e level of expression of this mRNA panel calculated 
as a type I interferon signature score (Figure 2) in an 
individual subject provides a continuous measurement 
that can be used to classify subpopulations of SLE 
patients. Th   e distribution of this type I interferon signa-
ture score in the WB of SLE patients exhibited a bimodal 
distribution, with relatively few SLE patient scores falling 
between subpopulations with normal levels and increased 
levels of expression (moderate and high over  expression) 
of the type I interferon signature (Figure 2). Th   is ability to 
diﬀ  erentiate between SLE patients with increased and 
normal expression of the type I interferon signature 
suggests potential utility of the type I interferon signature 
Figure 2. Distribution and density of type I interferon 
signature scores in systemic lupus erythematosus patients. (a) 
Distribution of the type I interferon signature scores in 202 systemic 
lupus erythematosus (SLE) patients measured at baseline. The 
type I interferon signature score is calculated as the median fold 
change (relative to a pooled normal healthy donor sample) of the 
21-member type I interferon-inducible transcript pharmacodynamic 
(PD) marker panel for each patient. The cut-off   point for an SLE 
patient scored as type I interferon signature positive was identifi  ed at 
a value of at least 2 (1 on a log2 scale), as represented by both the red 
points in (a) and the rightmost density in (b). Patients scored as type 
I interferon signature negative are represented by the blue points 
in and the leftmost density in (b). y axis, type I interferon signature 
score calculated for the 21-member mRNA PD marker panel on a 
log2 scale. x axis, type I interferon signature score calculated for the 
21-member transcript PD marker panel on a log2 scale. (b) Density 
plot of the type I interferon signature scores for these 202 SLE 
patients. Two distributional modes are illustrated, indicating a 
clear partitioning between the SLE populations of type I interferon 
signature positive and negative.
Figure 3. Sifalimumab inhibition of overexpression of the 
type I interferon signature in systemic lupus erythematosus 
patients. Dose responses of sifalimumab therapy in whole blood of 
systemic lupus erythematosus (SLE) patients with an overexpressed 
type I interferon-inducible gene signature as measured by the 
type I interferon-inducible gene signature score. Neutralization of 
the 21 type I interferon-inducible mRNAs by treatment averaged 
for each dose cohort observed from day 0 (pretreatment) to 
day 7 (posttreatment). y axis, values calculated as the fraction 
of neutralization of certain days post-treatment/pretreatment 
(day 0 predosing), subtracted from 1 for each patient separately. 
Those values that exceed 1 from this formula are a result of an 
increase in transcript levels of type I interferon-inducible mRNAs 
in whole blood following treatment (mostly in placebo-treated 
SLE patients). Signifi  cance for the diff  erence between dose levels 
and placebo treatment using Hotelling’s T2 test: 0.3 mg/kg, P =0.09; 
1 mg/kg, P =0.04; 3 mg/kg, P =0.01; 10 mg/kg, P =0.007; 30 mg/kg, 
P =0.004. From top to bottom: red line, placebo; blue line, 0.3 mg/kg 
sifalimumab; green line, 1 mg/kg sifalimumab; orange line, 3 mg/kg 
sifalimumab; black line, 10 mg/kg sifalimumab; pink line, 30 mg/kg 
sifalimumab.
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lation of SLE patients with increased expression of type I 
interferon. Th  is hypothesis remains to be validated in 
clinical trials.
Sifalimumab reduces the type I interferon 
signature in whole blood of SLE patients, in a 
dose-dependent manner
Th   e safety and tolerability of sifalimumab were evaluated 
in a phase 1 trial in 62 mild-to-moderately active adult 
SLE subjects who were receiving standard-of-care 
therapy [38,49]. Th   e trial evaluated intravenously adminis-
tered sifalimumab over a dose range of 0.3 to 30.0 mg/kg, 
compared with placebo. Th  e phase 1 trial integrated 
translational research to evaluate PD eﬀ  ects of the drug 
and downstream eﬀ  ects of inhibiting IFNα in SLE.
Sifalimumab caused speciﬁ  c and dose-dependent inhi-
bi  tion of overexpression of the type I interferon signature 
in WB of treated SLE subjects (Figure  3). Concordant 
overexpression of the type I interferon signature was 
observed in the majority of subjects who had matched 
WB and lesional skin biopsies [38]. Seven out of eight 
patients who exhibited positive overexpression of the 
type I interferon signature in WB and skin lesions showed 
a similar trend of target neutralization in both sites at day 
14 post sifalimumab or placebo treatment [38]. Inhibition 
of expression of both type I interferon-inducible mRNAs 
and protein occurred in skin lesions of SLE subjects, as 
measured by TaqMan quantitative RT-PCR and immuno-
histochemistry in subjects treated with sifalimumab. 
Reductions of plasmacytoid dendritic cells, myeloid 
dendritic cells, CD4+ T cells and dendritic cells were 
detected in the lesional skin of SLE patients, along with 
reduced levels of type I interferon-inducible mRNAs and 
proteins in patients who had skin biopsies that responded 
to sifalimumab treatment (Figure 4). Th   ese changes were 
not observed in the majority of the placebo-treated 
patients or in some subjects who did not respond to 
sifalimumab treatment, as evaluated by immunohisto-
chemistry [38]. In a small number of SLE subjects with 
overexpression of mRNAs of B-cell activating factor 
belonging to the TNF family and activation of TNFα, 
IL-10, IL-1β and granulocyte–macrophage colony-stimu-
lating factor signaling pathways in WB or skin lesions – 
as assessed by both TaqMan quantitative RT-PCR and 
microarray – a trend toward inhibition of the expression 
of these mRNAs was observed in response to sifalimumab 
treatment.
Results from this phase 1 trial showing dose-dependent 
inhibition of the type I interferon signature in the WB of 
SLE patients conﬁ   rmed the mechanism of action of 
sifalimumab. Th  e combination of concordant inhibition 
of the type I interferon signature in WB and involved skin 
and a reduction of type I interferon-inducible protein 
expression in skin in a phase 1a trial support further 
testing of sifalimumab in SLE. Genentech has recently 
Figure 4. Sifalimumab treatment in a responding systemic lupus erythematosus patient. Eff  ect of sifalimumab treatment in a single systemic 
lupus erythematosus patient who responded to 10 mg/kg drug treatment. (a) Immunohistochemical analyses of paired biopsies (days 0 predosing 
and day 14 postdosing) from lesional skin obtained from this patient. BDCA2 is a specifi  c marker for plasmacytoid dendritic cells, and CD83 is a 
marker for myeloid dendritic cells. IP10 is a type I interferon-inducible protein whose overexpression that was observed in lesional skin at day 0 
was decreased at day 14. There is a concordant reduction of IP10 protein expression and mRNA expression in the lesional skin of this patient with 
sifalimumab treatment. (b) Skin lesion clearance in this patient following sifalimumab treatment (day 0 predosing; days 7, 14, and 28 postdosing).
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bition of the type I interferon signature in the peripheral 
blood of SLE patients that followed either a single dose or 
repeat doses of rontalizumab, a humanized IgG1 
monoclonal antibody that also inhibits human IFNα [50]. 
Th   ese results con  ﬁ  rmed the potential usefulness of using 
the type I interferon signature as a PD marker to evaluate 
activity of anti-IFNα therapy in SLE. Furthermore, these 
studies showed that expression of the type I interferon 
signature in WB reﬂ   ects involved tissue in SLE, and 
raised the possibility of testing the type I interferon 
signature as a potential predictive biomarker to identify a 
subset of SLE patients who may preferentially respond to 
anti-IFNα treatment.
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